Overview

A Study of KHK4827 in Patients With Systemic Sclerosis

Status:
Active, not recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Exploratory evaluation of pharmacokinetics and safety of KHK4827 in subjects with systemic sclerosis
Phase:
Phase 1
Details
Lead Sponsor:
Kyowa Kirin Co., Ltd.
Treatments:
Brodalumab